RBPJ and MAML3: Potential therapeutic targets for small cell lung cancer

Hideya Ohnishi, Shu Ichimiya, Kosuke Yanai, Masayo Umebayashi, Katsuya Nakamura, Akio Yamasaki, Akira Imaizumi, Shuntaro Nagai, Mutsunori Murahashi, Hisanobu Ogata, Takashi Morisaki

研究成果: ジャーナルへの寄稿記事

1 引用 (Scopus)

抄録

Background/Aim: Small cell lung cancer (SCLC) is still a deadly type of cancer for which there are few effective therapeutic strategies. Development of a new molecule targeting agent is urgently desired. Previously we showed that recombination signal binding protein for immunoglobulin-kappa-J region (RBPJ) and mastermindlike 3 (MAML3) are new therapeutic targets for pancreatic cancer. In the present study, we analyzed whether RBPJ/MAML3 inhibition could also be a new therapeutic strategy for SCLC. Materials and Methods: Using silencing of RBPJ/MAML3, proliferation, invasion, migration and chemosensitivity of SBC-5 cells were investigated. Results: RBPJ/MAML3 inhibition reduced Smoothened and HES1 expression, suggesting that RBPJ/MAML3 signaling was through Hedgehog and NOTCH pathways. In the analysis of cell functions, RBPJ/MAML3 inhibition significantly reduced proliferation and invasiveness via reduction of expression of matrix metalloproteinases. On the other hand, RBPJ/MAML3 inhibition also reduced chemosensitivity to cis-diamminedichlo-roplatinum and gemcitabine. Conclusion: These results suggest that RBPJ and MAML3 could be new therapeutic targets for SCLC, however, chemosensitivity may be reduced in combinational use with other chemo-therapeutic agents.

元の言語英語
ページ(範囲)4543-4547
ページ数5
ジャーナルAnticancer research
38
発行部数8
DOI
出版物ステータス出版済み - 8 1 2018

Fingerprint

Small Cell Lung Carcinoma
gemcitabine
Therapeutics
Matrix Metalloproteinases
Pancreatic Neoplasms
Genetic Recombination
Immunoglobulins
Carrier Proteins
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Ohnishi, H., Ichimiya, S., Yanai, K., Umebayashi, M., Nakamura, K., Yamasaki, A., ... Morisaki, T. (2018). RBPJ and MAML3: Potential therapeutic targets for small cell lung cancer. Anticancer research, 38(8), 4543-4547. https://doi.org/10.21873/anticanres.12758

RBPJ and MAML3 : Potential therapeutic targets for small cell lung cancer. / Ohnishi, Hideya; Ichimiya, Shu; Yanai, Kosuke; Umebayashi, Masayo; Nakamura, Katsuya; Yamasaki, Akio; Imaizumi, Akira; Nagai, Shuntaro; Murahashi, Mutsunori; Ogata, Hisanobu; Morisaki, Takashi.

:: Anticancer research, 巻 38, 番号 8, 01.08.2018, p. 4543-4547.

研究成果: ジャーナルへの寄稿記事

Ohnishi, H, Ichimiya, S, Yanai, K, Umebayashi, M, Nakamura, K, Yamasaki, A, Imaizumi, A, Nagai, S, Murahashi, M, Ogata, H & Morisaki, T 2018, 'RBPJ and MAML3: Potential therapeutic targets for small cell lung cancer', Anticancer research, 巻. 38, 番号 8, pp. 4543-4547. https://doi.org/10.21873/anticanres.12758
Ohnishi H, Ichimiya S, Yanai K, Umebayashi M, Nakamura K, Yamasaki A その他. RBPJ and MAML3: Potential therapeutic targets for small cell lung cancer. Anticancer research. 2018 8 1;38(8):4543-4547. https://doi.org/10.21873/anticanres.12758
Ohnishi, Hideya ; Ichimiya, Shu ; Yanai, Kosuke ; Umebayashi, Masayo ; Nakamura, Katsuya ; Yamasaki, Akio ; Imaizumi, Akira ; Nagai, Shuntaro ; Murahashi, Mutsunori ; Ogata, Hisanobu ; Morisaki, Takashi. / RBPJ and MAML3 : Potential therapeutic targets for small cell lung cancer. :: Anticancer research. 2018 ; 巻 38, 番号 8. pp. 4543-4547.
@article{1c9917adeb8348368ed126eeb1b1630a,
title = "RBPJ and MAML3: Potential therapeutic targets for small cell lung cancer",
abstract = "Background/Aim: Small cell lung cancer (SCLC) is still a deadly type of cancer for which there are few effective therapeutic strategies. Development of a new molecule targeting agent is urgently desired. Previously we showed that recombination signal binding protein for immunoglobulin-kappa-J region (RBPJ) and mastermindlike 3 (MAML3) are new therapeutic targets for pancreatic cancer. In the present study, we analyzed whether RBPJ/MAML3 inhibition could also be a new therapeutic strategy for SCLC. Materials and Methods: Using silencing of RBPJ/MAML3, proliferation, invasion, migration and chemosensitivity of SBC-5 cells were investigated. Results: RBPJ/MAML3 inhibition reduced Smoothened and HES1 expression, suggesting that RBPJ/MAML3 signaling was through Hedgehog and NOTCH pathways. In the analysis of cell functions, RBPJ/MAML3 inhibition significantly reduced proliferation and invasiveness via reduction of expression of matrix metalloproteinases. On the other hand, RBPJ/MAML3 inhibition also reduced chemosensitivity to cis-diamminedichlo-roplatinum and gemcitabine. Conclusion: These results suggest that RBPJ and MAML3 could be new therapeutic targets for SCLC, however, chemosensitivity may be reduced in combinational use with other chemo-therapeutic agents.",
author = "Hideya Ohnishi and Shu Ichimiya and Kosuke Yanai and Masayo Umebayashi and Katsuya Nakamura and Akio Yamasaki and Akira Imaizumi and Shuntaro Nagai and Mutsunori Murahashi and Hisanobu Ogata and Takashi Morisaki",
year = "2018",
month = "8",
day = "1",
doi = "10.21873/anticanres.12758",
language = "English",
volume = "38",
pages = "4543--4547",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "8",

}

TY - JOUR

T1 - RBPJ and MAML3

T2 - Potential therapeutic targets for small cell lung cancer

AU - Ohnishi, Hideya

AU - Ichimiya, Shu

AU - Yanai, Kosuke

AU - Umebayashi, Masayo

AU - Nakamura, Katsuya

AU - Yamasaki, Akio

AU - Imaizumi, Akira

AU - Nagai, Shuntaro

AU - Murahashi, Mutsunori

AU - Ogata, Hisanobu

AU - Morisaki, Takashi

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Background/Aim: Small cell lung cancer (SCLC) is still a deadly type of cancer for which there are few effective therapeutic strategies. Development of a new molecule targeting agent is urgently desired. Previously we showed that recombination signal binding protein for immunoglobulin-kappa-J region (RBPJ) and mastermindlike 3 (MAML3) are new therapeutic targets for pancreatic cancer. In the present study, we analyzed whether RBPJ/MAML3 inhibition could also be a new therapeutic strategy for SCLC. Materials and Methods: Using silencing of RBPJ/MAML3, proliferation, invasion, migration and chemosensitivity of SBC-5 cells were investigated. Results: RBPJ/MAML3 inhibition reduced Smoothened and HES1 expression, suggesting that RBPJ/MAML3 signaling was through Hedgehog and NOTCH pathways. In the analysis of cell functions, RBPJ/MAML3 inhibition significantly reduced proliferation and invasiveness via reduction of expression of matrix metalloproteinases. On the other hand, RBPJ/MAML3 inhibition also reduced chemosensitivity to cis-diamminedichlo-roplatinum and gemcitabine. Conclusion: These results suggest that RBPJ and MAML3 could be new therapeutic targets for SCLC, however, chemosensitivity may be reduced in combinational use with other chemo-therapeutic agents.

AB - Background/Aim: Small cell lung cancer (SCLC) is still a deadly type of cancer for which there are few effective therapeutic strategies. Development of a new molecule targeting agent is urgently desired. Previously we showed that recombination signal binding protein for immunoglobulin-kappa-J region (RBPJ) and mastermindlike 3 (MAML3) are new therapeutic targets for pancreatic cancer. In the present study, we analyzed whether RBPJ/MAML3 inhibition could also be a new therapeutic strategy for SCLC. Materials and Methods: Using silencing of RBPJ/MAML3, proliferation, invasion, migration and chemosensitivity of SBC-5 cells were investigated. Results: RBPJ/MAML3 inhibition reduced Smoothened and HES1 expression, suggesting that RBPJ/MAML3 signaling was through Hedgehog and NOTCH pathways. In the analysis of cell functions, RBPJ/MAML3 inhibition significantly reduced proliferation and invasiveness via reduction of expression of matrix metalloproteinases. On the other hand, RBPJ/MAML3 inhibition also reduced chemosensitivity to cis-diamminedichlo-roplatinum and gemcitabine. Conclusion: These results suggest that RBPJ and MAML3 could be new therapeutic targets for SCLC, however, chemosensitivity may be reduced in combinational use with other chemo-therapeutic agents.

UR - http://www.scopus.com/inward/record.url?scp=85050797895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050797895&partnerID=8YFLogxK

U2 - 10.21873/anticanres.12758

DO - 10.21873/anticanres.12758

M3 - Article

C2 - 30061220

AN - SCOPUS:85050797895

VL - 38

SP - 4543

EP - 4547

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 8

ER -